BC
HAE icon

Broadfin Capital’s Haemonetics HAE Stock Holding History

Broadfin Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3,600
Closed -$127K – 74
2014
Q2 		$127K Buy
+3,600
New +$120K 0.01% 70

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Broadfin Capital's HAE Position: Q3 2014 in Review

Broadfin Capital sold out of Haemonetics (HAE) in Q3 2014, closing a stake of 3,600 shares — an estimated $127K sold.

Broadfin Capital first reported a position in HAE in Q2 2014 and held it in 1 quarter. The position peaked at $127K in Q2 2014. 170 funds tracked by Wall St. Rank hold HAE as of Q3 2014.

  • Broadfin Capital reported no remaining Haemonetics position as of Q3 2014 after selling out during the quarter.
  • Broadfin Capital sold 3,600 Haemonetics shares in Q3 2014, an estimated $127K.
  • Broadfin Capital first reported a position in Haemonetics in Q2 2014 and held it in 1 quarter.
  • Broadfin Capital's Haemonetics position peaked at $127K in Q2 2014.
  • 170 funds tracked by Wall St. Rank held Haemonetics as of Q3 2014.

Based on Broadfin Capital's 13F filing for Q3 2014, filed 14 Nov 2014.